The Journal of the Association of Physicians of India · 2025
Association of Physicians of India Consensus Recommendations for Vonoprazan in Management of Acid Peptic Disorders.
СтатьяConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Upadhyay Rajesh, Soni N K, Vora Agam, Saraf Amit, Haldipur Deepak, Mukherjee Dwaipayan, Das Dwijen, Tiwaskar Mangesh, Nadkar Milind, Arun N, Kumar Rajesh B, Bhadade Rakesh, Rai Ramesh R, Bhargava Samir, Parikh Samir, Shetty Shiran, Kant Surya, Jalihal Umesh, Prasad V G Mohan, Kotamkar Ashwin, Pallewar Shailesh, Qamra Amit
Аннотация
The suppression of gastric acid secretion has long been the cornerstone of treatment for acid peptic disorders (APDs). Proton pump inhibitors (PPIs) have played a central role in managing these conditions, but their effectiveness can be hindered by notable limitations such as refractoriness or treatment failure due to inadequate acid suppression in some gastroesophageal reflux disease (GERD) patients, nonadherence to prescribed regimens due to the complexity of dosing, variability of response, and nocturnal acid breakthrough, etc. Vonoprazan is a first-in-class potassium-competitive acid blocker (P-CAB), recently introduced in India and also approved in several countries such as Japan, South Korea, and the USA. Extensive clinical evidence suggests that vonoprazan offers more potent acid suppression than PPIs. This consensus from the Association of Physicians of India (API) has been developed with the objective of providing key recommendations for the appropriate clinical usage of vonoprazan across various subsets of APDs, thereby optimizing the existing therapeutic options and improving the care and management of APD patients.